Our Industry Leading Speakers | Kisaco Research

Our Industry Leading Speakers

AI Driven Drug Discovery Summit USA
12-14 November, 2024
Boston, United States
  • Author:

    Robert Goodnow

    Head of Drug Discovery Sciences
    Takeda

    Robert Goodnow

    Head of Drug Discovery Sciences
    Takeda
  • Author:

    Peter Clark

    VP Computational Drug Design
    Novo Nordisk

    Peter Clark

    VP Computational Drug Design
    Novo Nordisk
  • Author:

    Jacob Berlin

    CEO
    Terray Therapeutics

    Jacob Berlin

    CEO
    Terray Therapeutics
  • Author:

    Mark Adams

    Venture Capital Partner
    Two Bear Capital

    Mark Adams

    Venture Capital Partner
    Two Bear Capital
  • Author:

    Lu Zhang

    Founder & Managing Partner
    Fusion Fund

    Lu Zhang

    Founder & Managing Partner
    Fusion Fund
  • Author:

    Zachary Webel

    Data Scientist and Applied Mathematician
    FDA

    Zachary Webel

    Data Scientist and Applied Mathematician
    FDA
  • Author:

    Lena Dolgikh

    Head of Computational Chemistry
    Monte Rosa Therapeutics

    Lena Dolgikh

    Head of Computational Chemistry
    Monte Rosa Therapeutics
  • Author:

    Ed Addison

    Executive Chairman & Acting CEO
    CLOUD PHARMACEUTICALS

    Ed Addison

    Executive Chairman & Acting CEO
    CLOUD PHARMACEUTICALS
  • Author:

    Zhiyong (Sean) Xie

    VP & Head of AI & Data Science
    Xellarbio

    Zhiyong (Sean) Xie

    VP & Head of AI & Data Science
    Xellarbio
  • Author:

    Arvind Rao

    Associate Professor Computational Medicine & Bioinformatics
    University of Michigan

    Arvind Rao

    Associate Professor Computational Medicine & Bioinformatics
    University of Michigan
  • Author:

    Monica Wang

    Head of Biologics & Novel Modality Discovery Capabilities & Products, Scientific Informatics
    Takeda

    Monica Wang

    Head of Biologics & Novel Modality Discovery Capabilities & Products, Scientific Informatics
    Takeda
  • Author:

    Simon Beaulah

    SVP Precision Drug Repositioning
    PRECISIONLIFE

    Simon Beaulah

    SVP Precision Drug Repositioning
    PRECISIONLIFE
  • Author:

    Petrina Kamya

    Global Head of AI Platforms, VP Insilico Medicine President
    Insilico Medicine Canada Inc.

    Petrina Kamya

    Global Head of AI Platforms, VP Insilico Medicine President
    Insilico Medicine Canada Inc.
  • Author:

    Rohit Arora

    Innovation Lead
    Novo Nordisk

    Rohit Arora

    Innovation Lead
    Novo Nordisk
  • Author:

    Ari Allyn-Feuer

    Director AI Product
    GSK

    Ari Allyn-Feuer

    Director AI Product
    GSK
  • Author:

    Karen Akinsanya

    President R&D
    Schrodinger

    Karen Akinsanya

    President R&D
    Schrodinger
  • Author:

    Sriram Chandrasekaran

    Associate Professor, Biomedical Engineering
    University of Michigan

    Sriram Chandrasekaran

    Associate Professor, Biomedical Engineering
    University of Michigan
  • Author:

    Mani Foroohar

    Senior Managing Director Biotechnology Analyst
    Leerink

    Mani Foroohar

    Senior Managing Director Biotechnology Analyst
    Leerink
  • Author:

    Nevin Gerek Ince

    Director Data & Solutions Engineering
    Novo Nordisk

    Nevin Gerek Ince

    Director Data & Solutions Engineering
    Novo Nordisk
  • Author:

    Zoran Krunic

    Principal Product Manager
    Amgen

    Since joining Amgen R&D in 2018, Zoran Krunic has been at the forefront of applying Machine Learning to enhance patient outcomes and streamline clinical trial enrollment processes, utilizing comprehensive Electronic Health Records and clinical datasets. His pioneering work in the Quantum Machine Learning space, in collaboration with IBM's Quantum team, has been instrumental in integrating machine learning with quantum computing through IBM’s Qiskit platform.

    Prior to his tenure at Amgen, Zoran developed Machine Learning algorithms at Optum to predict hardware and software failures within complex enterprise architectures. He has a strong background in data engineering and systems development, having contributed significantly to large-scale projects at renowned organizations such as Capital Group and ARCO Petroleum.

    In his current full and part-time endeavors, Zoran is leading the efforts in embracing generative AI technologies, with a particular focus on OpenAI's GPT and Anthropic's Claude-2 models. His work is focused on prompt engineering and its application to code generation, advanced document analysis, and process management, with a commitment to ethical AI practices and data privacy.

    A recognized voice in quantum computing circles, Zoran is a regular presenter at industry conferences and has served on numerous panels discussing the integration of quantum computing and generative AI within the Health Sciences sector.

    With a Master of Science in Electrical Engineering & Computer Science, Zoran continues to explore and contribute to the evolving relationship between quantum computing and artificial intelligence, fostering groundbreaking advancements in healthcare technology.

    Zoran Krunic

    Principal Product Manager
    Amgen

    Since joining Amgen R&D in 2018, Zoran Krunic has been at the forefront of applying Machine Learning to enhance patient outcomes and streamline clinical trial enrollment processes, utilizing comprehensive Electronic Health Records and clinical datasets. His pioneering work in the Quantum Machine Learning space, in collaboration with IBM's Quantum team, has been instrumental in integrating machine learning with quantum computing through IBM’s Qiskit platform.

    Prior to his tenure at Amgen, Zoran developed Machine Learning algorithms at Optum to predict hardware and software failures within complex enterprise architectures. He has a strong background in data engineering and systems development, having contributed significantly to large-scale projects at renowned organizations such as Capital Group and ARCO Petroleum.

    In his current full and part-time endeavors, Zoran is leading the efforts in embracing generative AI technologies, with a particular focus on OpenAI's GPT and Anthropic's Claude-2 models. His work is focused on prompt engineering and its application to code generation, advanced document analysis, and process management, with a commitment to ethical AI practices and data privacy.

    A recognized voice in quantum computing circles, Zoran is a regular presenter at industry conferences and has served on numerous panels discussing the integration of quantum computing and generative AI within the Health Sciences sector.

    With a Master of Science in Electrical Engineering & Computer Science, Zoran continues to explore and contribute to the evolving relationship between quantum computing and artificial intelligence, fostering groundbreaking advancements in healthcare technology.

  • Author:

    Hayley Donnella

    Director of Computational Oncology
    Recursion

    Hayley Donnella

    Director of Computational Oncology
    Recursion
  • Author:

    Lauris Kemp

    Partner & Patent Attorney
    HGF

    Lauris Kemp

    Partner & Patent Attorney
    HGF
  • Author:

    Daniyal Hussain

    Executive Director of Technology Business Development
    GSK

    Daniyal Hussain

    Executive Director of Technology Business Development
    GSK
  • Author:

    Yu Qiu

    Head of AI Innovation - Antibody Digital Biologics Platform
    Sanofi

    Yu Qiu

    Head of AI Innovation - Antibody Digital Biologics Platform
    Sanofi
  • Author:

    Serhat Tetikol

    Associate Director
    Bristol Myers Squibb

    Serhat Tetikol

    Associate Director
    Bristol Myers Squibb
  • Author:

    Yang-ming Zhu

    SVP Head of Engineering (AI & ML)
    Superluminal

    Yang-ming Zhu

    SVP Head of Engineering (AI & ML)
    Superluminal
  • Author:

    Chirag Sacher

    Director Portfolio Innovation
    Novartis

    Chirag Sacher

    Director Portfolio Innovation
    Novartis
  • Author:

    Julian Hess

    Computational Scientist
    Broad Institute of MIT & Harvard

    Julian Hess

    Computational Scientist
    Broad Institute of MIT & Harvard
  • Author:

    Elena Diaz Cecilia

    Senior Director, External Innovation
    Janssen R&D

    Elena Diaz Cecilia

    Senior Director, External Innovation
    Janssen R&D
  • Author:

    Peter McLean

    Director Data Science
    Recursion

    Peter McLean

    Director Data Science
    Recursion
  • Author:

    Claire Leurent

    Managing Director
    Abbvie Ventures

    Claire Leurent

    Managing Director
    Abbvie Ventures
  • Author:

    Aiden Acever

    VP
    Insight Partners

    Aiden Acever

    VP
    Insight Partners
  • Author:

    Xia Ning

    Professor
    Ohio State University

    Xia Ning

    Professor
    Ohio State University
  • Author:

    Jackie Hunter

    CEO
    OI Pharma Partners

    Jackie Hunter

    CEO
    OI Pharma Partners
  • Author:

    Ethan Pickering

    Head of Data Science & Machine Learning Research
    Bayer

    Ethan Pickering

    Head of Data Science & Machine Learning Research
    Bayer
  • Author:

    Soujanya Bhumkar

    Co-Founder
    Gen1e Lifesciences

    Soujanya Bhumkar

    Co-Founder
    Gen1e Lifesciences
  • Author:

    Ashwini Ghogare

    Head of AI & Automation in Drug Discovery
    MilliporeSigma

    Ashwini Ghogare

    Head of AI & Automation in Drug Discovery
    MilliporeSigma
  • Author:

    Charles O’Donnell

    Vice President Head of Computational Genomics & Data Sciences
    Omega Therapeutics

    Charles O’Donnell

    Vice President Head of Computational Genomics & Data Sciences
    Omega Therapeutics
  • Author:

    Brendan Frey

    Founder & Chief Innovation Officer
    Deep Genomics

    Brendan Frey

    Founder & Chief Innovation Officer
    Deep Genomics
  • Author:

    Duncan Ng

    Vice President, Solutions Engineering
    Vultr

    Duncan Ng is Vultr's Vice President, Solutions Engineering. Duncan leads Vultr's Pre-Sales, Technical Account Management, and Partner Engineering organization. In this role he spearheads Vultr's global Technical Sales strategy and execution for Vultr customers through their entire customer journey. Duncan has decades of experience in delivering hyperscale offerings across domains including high performance computing, network engineering, data center infrastructure, and white & gray-space fit out. Previously Duncan held roles at Earthlink, Eaton, and BPR Advisory.

    Duncan Ng

    Vice President, Solutions Engineering
    Vultr

    Duncan Ng is Vultr's Vice President, Solutions Engineering. Duncan leads Vultr's Pre-Sales, Technical Account Management, and Partner Engineering organization. In this role he spearheads Vultr's global Technical Sales strategy and execution for Vultr customers through their entire customer journey. Duncan has decades of experience in delivering hyperscale offerings across domains including high performance computing, network engineering, data center infrastructure, and white & gray-space fit out. Previously Duncan held roles at Earthlink, Eaton, and BPR Advisory.